Co-Diagnostics unveils CoMira JV for MENA diagnostic manufacturing at Dubai expo

Co-Diagnostics pushes regional manufacturing via CoMira at Dubai expo

SALT LAKE CITY — Co-Diagnostics is using a major regional trade show to press its plan to localize manufacturing and distribution across the Middle East and North Africa (MENA). The molecular diagnostics company exhibits at World Health Expo Labs Dubai on Feb. 10–13, where it presents the commercial case for a newly formed joint venture, CoMira Diagnostics, with Arabian Eagle Manufacturing in Saudi Arabia. Company executives say the arrangement aims to enable local production, regulatory alignment and faster deployment of molecular tests across Saudi Arabia and 18 additional MENA countries.

The joint venture forms the centerpiece of Co-Diagnostics’ strategy to engage health ministries, hospital laboratories and private diagnostic chains at the Dubai World Trade Centre. Co-Diagnostics positions CoMira as a vehicle to transfer technology, scale manufacturing capacity in the region and create local jobs while adapting product workflows to regional regulatory and market needs. Company representatives are meeting regional stakeholders at the World Trade Center Utah booth to pursue distribution partnerships and pilot programs that leverage the joint venture’s local footprint.

Co-Diagnostics frames the exhibition as part of a broader effort to accelerate access to its nucleic acid–based diagnostic platform throughout MENA. Officials highlight that localized manufacturing and licensing could shorten supply chains for molecular assays, reduce import dependencies for critical reagents and support faster regulatory submissions by combining U.S. technical data with regional validation studies. The company emphasizes that the initiative seeks to align production capacity with clinical demand across a diverse set of public health and private sector customers in 19 countries.

Showcasing the Co-Dx PCR system

At the expo Co-Diagnostics showcases its Co-Dx PCR platform, which comprises PCR Home, PCR Pro, an associated mobile app and a suite of test applications. The company says the platform is undergoing clinical studies in the United States and remains subject to FDA and other regulatory review; the system and its licensed tests are not yet available for sale.

Company profile and regional aim

Co-Diagnostics, a Utah-based developer and manufacturer of molecular diagnostics that detect DNA and RNA, intends to leverage its patented chemistry and software to expand regional access to high-quality molecular testing. The firm frames the CoMira partnership as advancing technology transfer, local capacity building and broader deployment of molecular diagnostics across the MENA market.